Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ECC0509 in Healthy Volunteers
NCT05012423Phase 1Completed
- Sponsor
- Eccogene
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ECC0509 in Nonalcoholic steatohepatitis (NASH) and osteoarthritis (OA) (4 arms), sponsored by Eccogene. Primary endpoint: Number of participants with adverse events. Started Jul 2021; status: completed.
02
Drugs
ECC0509
03
Conditions
Nonalcoholic steatohepatitis (NASH)osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05012423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012423.